Herpesvirus Antiviral Resistance
Database
Language
English
French
Spanish
German
CNR Website
Home
Login
Data
All data
Antivirals
Bibliography
Therapeutic targets
Tools
Search
Submit mutations
Request expertise
Genotyping tool
Contact
Notice
Last update : Wed 22 May 2024
TOP
Letermovir
Short name: LMV
Chembl ID:
CHEMBL1241951
SMILES (Simplified Molecular Input Line Entry System): COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
Assays:
Filter:
Mutant
Gene
Type
Virus
EC50 ratio
Phenotype
Assay
Reference
D12E
UL51
SNP
Human betaherpesvirus 5
1.40
No resistance
Details
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
E17del
UL51
in/del
Human betaherpesvirus 5
1.30
No resistance
Details
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
P91S
UL51
SNP
Human betaherpesvirus 5
2.10
Low level resistance
Details
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
A95V
UL51
SNP
Human betaherpesvirus 5
13.80
High level resistance
Details
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
V113L
UL51
SNP
Human betaherpesvirus 5
1.50
No resistance
Details
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
C25F
UL56
SNP
Human betaherpesvirus 5
5.40
High level resistance
Details
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
S229F
UL56
SNP
Human betaherpesvirus 5
1.80
No resistance
Details
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
V231A
UL56
SNP
Human betaherpesvirus 5
2.10
Low level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
V231L
UL56
SNP
Human betaherpesvirus 5
5.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
N232Y
UL56
SNP
Human betaherpesvirus 5
17.00
High level resistance
Details
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
V236A
UL56
SNP
Human betaherpesvirus 5
2.90
Low level resistance
Details
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
V236L
UL56
SNP
Human betaherpesvirus 5
14.00
High level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
V236M
UL56
SNP
Human betaherpesvirus 5
45.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
E237D
UL56
SNP
Human betaherpesvirus 5
10.00
High level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
L241P
UL56
SNP
Human betaherpesvirus 5
218.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
T244K
UL56
SNP
Human betaherpesvirus 5
3.30
Intermediate level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
L254F
UL56
SNP
Human betaherpesvirus 5
3.20
Intermediate level resistance
Details
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
L257F
UL56
SNP
Human betaherpesvirus 5
8.60
High level resistance
Details
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
L257I
UL56
SNP
Human betaherpesvirus 5
4.90
Intermediate level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
K258E
UL56
SNP
Human betaherpesvirus 5
14.00
High level resistance
Details
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
F261C
UL56
SNP
Human betaherpesvirus 5
4.40
Intermediate level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
F261L
UL56
SNP
Human betaherpesvirus 5
2.80
Low level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
Y321C
UL56
SNP
Human betaherpesvirus 5
4.60
Intermediate level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
C325F
UL56
SNP
Human betaherpesvirus 5
3000.00
High level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
C325R
UL56
SNP
Human betaherpesvirus 5
3000.00
High level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
C325Y
UL56
SNP
Human betaherpesvirus 5
8796.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
C325W
UL56
SNP
Human betaherpesvirus 5
9300.00
High level resistance
Details
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
L328V
UL56
SNP
Human betaherpesvirus 5
1.90
No resistance
Details
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
M329T
UL56
SNP
Human betaherpesvirus 5
4.40
Intermediate level resistance
Details
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
F345L
UL56
SNP
Human betaherpesvirus 5
0.95-1.03
Range of values of No resistance
Details
Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
A365S
UL56
SNP
Human betaherpesvirus 5
2.00
Low level resistance
Details
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
N368D
UL56
SNP
Human betaherpesvirus 5
2.00
Low level resistance
Details
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
R369T
UL56
SNP
Human betaherpesvirus 5
52.00
High level resistance
Details
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020)
R369G
UL56
SNP
Human betaherpesvirus 5
44.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
R369M
UL56
SNP
Human betaherpesvirus 5
13.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
R369S
UL56
SNP
Human betaherpesvirus 5
48.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
R396S
UL56
SNP
Human betaherpesvirus 5
81.00
High level resistance
Details
Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
N320H
UL89
SNP
Human betaherpesvirus 5
1.80
No resistance
Details
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
N329S
UL89
SNP
Human betaherpesvirus 5
2.00
Low level resistance
Details
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
D344E
UL89
SNP
Human betaherpesvirus 5
1.80
No resistance
Details
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
T350M
UL89
SNP
Human betaherpesvirus 5
2.80
Low level resistance
Details
Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
M359I
UL89
SNP
Human betaherpesvirus 5
1.50
No resistance
Details
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)